Podcast: Gibbons Institute Hosts Panel on Pay for Delay in Hatch-Waxman Patent Litigation
Posted Sep 17 2010 8:51am
Seton Hall Law’s Gibbons Institute of Law, Science & Technology and the New Jersey Intellectual Property Law Association presented a panel discussion entitled, “Pay for Delay: Views from the FTC, Industry and Legal Economists on Reverse Payment Settlements in Hatch-Waxman Patent Litigation.”
The pay for delay debate essentially rests on two competing public interests: scientific innovation and access to medicines. Reverse settlements, which are sometimes referred to as “pay for delay,” involve the practice of name-brand pharmaceutical companies paying would-be generic competitors to delay the entry into the market of a particular generic drug. The Federal Trade Commission and the Department of Justice decry the practice because they claim it results in higher prices for consumers who do not have access to cheaper generics. Many in the brand-name pharmaceutical industry defend the practice because, they argue, extending the patent exclusivity period of an innovator drug better allows innovator companies to improve their return on investment and thus underwrite further research and innovation.
Panelists included Michael Kades, Attorney Advisor, Federal Trade Commission; Charles A. Gallia, Counsel, Gibbons P.C.; Anastasia Winslow, Assistant General Counsel, Bristol-Myers Squibb; and David Opderbeck, Associate Professor of Law and Director, Gibbons Institute of Law, Science & Technology. You can listen to their discussion here.